In new independent research reports released early this morning,
Fundamental Markets released its latest key findings for all
current investors, traders, and shareholders of eBay Inc.
(NASDAQ:EBAY), Maxwell Technologies, Inc. (NASDAQ:MXWL), The
Priceline Group Inc. (NASDAQ:PCLN), Allscripts Healthcare
Solutions, Inc. (NASDAQ:MDRX), Ziopharm Oncology Inc (NASDAQ:ZIOP),
and H&R Block, Inc. (NYSE:HRB), including updated fundamental
summaries, consolidated fiscal reporting, and fully-qualified
certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
EBAY DOWNLOAD:
http://Fundamental-Markets.com/register/?so=EBAY
MXWL DOWNLOAD:
http://Fundamental-Markets.com/register/?so=MXWL
PCLN DOWNLOAD:
http://Fundamental-Markets.com/register/?so=PCLN
MDRX DOWNLOAD:
http://Fundamental-Markets.com/register/?so=MDRX
ZIOP DOWNLOAD:
http://Fundamental-Markets.com/register/?so=ZIOP
HRB DOWNLOAD:
http://Fundamental-Markets.com/register/?so=HRB
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Fundamental Markets, available for
free download at the links above, examine eBay Inc. (NASDAQ:EBAY),
Maxwell Technologies, Inc. (NASDAQ:MXWL), The Priceline Group Inc.
(NASDAQ:PCLN), Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX),
Ziopharm Oncology Inc (NASDAQ:ZIOP), and H&R Block, Inc.
(NYSE:HRB) on a fundamental level and outlines the overall demand
for their products and services in addition to an in-depth review
of the business strategy, management discussion, and overall
direction going forward. Several excerpts from the recently
released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are
not designed to be standalone summaries and as such, important
information may be missing from these samples. All information in
this release was accessed November 24th, 2017. Please download the
entire research report, free of charge, to ensure you are reading
all relevant material information. All amounts in millions (MM),
except per share amounts. Percentage calculations are performed
after rounding.
-----------------------------------------
EBAY INC. (EBAY) REPORT OVERVIEW
eBay's Recent Financial Performance
For the three months ended September 30th, 2017 vs September
30th, 2016, eBay reported revenue of $2,409.00MM vs $2,217.00MM (up
8.66%) and diluted earnings per share $0.48 vs $0.36 (up 33.33%).
For the twelve months ended December 31st, 2016 vs December 31st,
2015, eBay reported revenue of $8,979.00MM vs $8,592.00MM (up
4.50%) and diluted earnings per share $6.35 vs $1.42 (up 347.18%).
eBay is expected to report earnings on January 24th, 2018. The
report will be for the fiscal period ending December 31st, 2017.
The reported EPS for the same quarter last year was $0.44. The
estimated EPS forecast for the next fiscal year is $1.83 and is
expected to report on January 24th, 2018.
To read the full eBay Inc. (EBAY) report, download it here:
http://Fundamental-Markets.com/register/?so=EBAY
-----------------------------------------
MAXWELL TECHNOLOGIES, INC. (MXWL) REPORT
OVERVIEW
Maxwell Technologies' Recent Financial
Performance
For the three months ended September 30th, 2017 vs September
30th, 2016, Maxwell Technologies reported revenue of $35.82MM vs
$25.51MM (up 40.42%) and diluted earnings per share -$0.37 vs
-$0.21. For the twelve months ended December 31st, 2016 vs December
31st, 2015, Maxwell Technologies reported revenue of $121.24MM vs
$167.37MM (down 27.56%) and diluted earnings per share -$0.74 vs
-$0.73. Maxwell Technologies is expected to report earnings on
February 27th, 2018. The report will be for the fiscal period
ending December 31st, 2017. The reported EPS for the same quarter
last year was -$0.28. The estimated EPS forecast for the next
fiscal year is -$0.60 and is expected to report on February 27th,
2018.
To read the full Maxwell Technologies, Inc. (MXWL) report,
download it here:
http://Fundamental-Markets.com/register/?so=MXWL
-----------------------------------------
THE PRICELINE GROUP INC. (PCLN) REPORT
OVERVIEW
The Priceline Group's Recent Financial
Performance
For the three months ended September 30th, 2017 vs September
30th, 2016, The Priceline Group reported revenue of $4,434.03MM vs
$3,690.55MM (up 20.15%) and diluted earnings per share $34.43 vs
$10.13 (up 239.88%). For the twelve months ended December 31st,
2016 vs December 31st, 2015, The Priceline Group reported revenue
of $10,743.01MM vs $9,223.99MM (up 16.47%) and diluted earnings per
share $42.65 vs $49.45 (down 13.75%). The Priceline Group is
expected to report earnings on February 26th, 2018. The report will
be for the fiscal period ending December 31st, 2017. The reported
EPS for the same quarter last year was $14.21. The estimated EPS
forecast for the next fiscal year is $84.29 and is expected to
report on February 26th, 2018.
To read the full The Priceline Group Inc. (PCLN) report,
download it here:
http://Fundamental-Markets.com/register/?so=PCLN
-----------------------------------------
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (MDRX) REPORT
OVERVIEW
Allscripts Healthcare Solutions' Recent Financial
Performance
For the three months ended September 30th, 2017 vs September
30th, 2016, Allscripts Healthcare Solutions reported revenue of
$449.44MM vs $392.38MM (up 14.54%) and diluted earnings per share
-$0.16 vs -$0.06. For the twelve months ended December 31st, 2016
vs December 31st, 2015, Allscripts Healthcare Solutions reported
revenue of $1,549.90MM vs $1,386.39MM (up 11.79%) and diluted
earnings per share -$0.14 vs -$0.01. Allscripts Healthcare
Solutions is expected to report earnings on February 15th, 2018.
The report will be for the fiscal period ending December 31st,
2017. The reported EPS for the same quarter last year was $0.10.
The estimated EPS forecast for the next fiscal year is $0.58 and is
expected to report on February 15th, 2018.
To read the full Allscripts Healthcare Solutions, Inc. (MDRX)
report, download it here:
http://Fundamental-Markets.com/register/?so=MDRX
-----------------------------------------
ZIOPHARM ONCOLOGY INC (ZIOP) REPORT
OVERVIEW
Ziopharm Oncology's Recent Financial
Performance
For the three months ended September 30th, 2017 vs September
30th, 2016, Ziopharm Oncology reported revenue of $1.60MM vs
$1.60MM (unchanged) and diluted earnings per share -$0.13 vs
-$0.11. For the twelve months ended December 31st, 2016 vs December
31st, 2015, Ziopharm Oncology reported revenue of $6.86MM vs
$4.33MM (up 58.38%) and diluted earnings per share -$1.32 vs
-$0.96. Ziopharm Oncology is expected to report earnings on
February 15th, 2018. The report will be for the fiscal period
ending December 31st, 2017. The reported EPS for the same quarter
last year was -$0.11. The estimated EPS forecast for the next
fiscal year is -$0.56 and is expected to report on February 15th,
2018.
To read the full ZIOPHARM Oncology Inc (ZIOP) report, download
it here:
http://Fundamental-Markets.com/register/?so=ZIOP
-----------------------------------------
H&R BLOCK, INC. (HRB) REPORT OVERVIEW
H&R Block's Recent Financial
Performance
For the three months ended July 31st, 2017 vs July 31st, 2016,
H&R Block reported revenue of $137.80MM vs $125.19MM (up
10.08%) and diluted earnings per share -$0.63 vs -$0.56. For the
twelve months ended April 30th, 2017 vs April 30th, 2016, H&R
Block reported revenue of $3,036.31MM vs $3,038.15MM (down 0.06%)
and diluted earnings per share $1.91 vs $1.49 (up 28.19%). H&R
Block is expected to report earnings on December 6th, 2017. The
report will be for the fiscal period ending October 31st, 2017. The
reported EPS for the same quarter last year was -$0.67. The
estimated EPS forecast for the next fiscal year is $2.03 and is
expected to report on June 12th, 2018.
To read the full H&R Block, Inc. (HRB) report, download it
here:
http://Fundamental-Markets.com/register/?so=HRB
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have
provided research through some of the world's leading brokerages
for over a decade–and continue to be one of the best information
sources for investors and investment professionals worldwide.
Fundamental Markets' roster boasts decades of financial experience
and includes top financial writers, FINRA® BrokerCheck® certified
professionals with current and valid CRD® number designations, as
well as Chartered Financial Analyst® (CFA®) designation holders, to
ensure up to date factual information for active readers on the
topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered
analysts, brokers, and/or financial advisers ("Registered Members")
working within Equity Research, Media, and Compliance departments.
Fundamental Markets' roster includes qualified CFA® charterholders,
licensed securities attorneys, and registered FINRA® members
holding duly issued CRD® numbers. Current licensed status of
several Registered Members at Fundamental Markets have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Fundamental Markets' Compliance department by Phone, at
+1 667-401-0010, or by E-mail at
compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to
buy, hold, or sell any security. Fundamental Markets, Fundamental
Markets members, and/or Fundamental Markets affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Fundamental Markets makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Fundamental
Markets has not been compensated for the publication of this press
release by any of the above mentioned companies. Fundamental
Markets is not a financial advisory firm, investment adviser, or
broker-dealer, and does not undertake any activities that would
require such registration. For our full disclaimer, disclosure, and
terms of service please visit our website.
Media Contact: Andrew Duffie, Media Department
Office: +1 667-401-0010 E-mail: media@Fundamental-Markets.com
© 2017 Fundamental Markets. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Aug 2024 to Sep 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Sep 2023 to Sep 2024